Home > Research > Publications & Outputs > Staphylococcus aureus strains exhibit heterogen...

Links

Text available via DOI:

View graph of relations

Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy. / Baz, Abdullah; Bakri, Ahmed; Butcher, Mark et al.
In: Biofilm, Vol. 5, 100123, 31.12.2023.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Baz, A., Bakri, A., Butcher, M., Short, B., Ghimire, B., Gaur, N., Jenkins, T., Short, R. D., Riggio, M., Williams, C., Ramage, G., & Brown, J. L. (2023). Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy. Biofilm, 5, Article 100123. https://doi.org/10.1016/j.bioflm.2023.100123

Vancouver

Baz A, Bakri A, Butcher M, Short B, Ghimire B, Gaur N et al. Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy. Biofilm. 2023 Dec 31;5:100123. Epub 2023 Apr 22. doi: 10.1016/j.bioflm.2023.100123

Author

Baz, Abdullah ; Bakri, Ahmed ; Butcher, Mark et al. / Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy. In: Biofilm. 2023 ; Vol. 5.

Bibtex

@article{68fb5976e3f94949abf762c719102e4b,
title = "Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy",
abstract = "The global clinical and socioeconomic impact of chronic wounds is substantial. The main difficulty that clinicians face during the treatment of chronic wounds is the risk of infection at the wound site. Infected wounds arise from an accumulation of microbial aggregates in the wound bed, leading to the formation of polymicrobial biofilms that can be largely resistant to antibiotic therapy. Therefore, it is essential for studies to identify novel therapeutics to alleviate biofilm infections. One innovative technique is the use of cold atmospheric plasma (CAP) which has been shown to possess promising antimicrobial and immunomodulatory properties. Here, different clinically relevant biofilm models will be treated with cold atmospheric plasma to assess its efficacy and killing effects. Biofilm viability was assessed using live dead qPCR, and morphological changes associated with CAP evaluated using scanning electron microscopy (SEM). Results indicated that CAP was effective against Candida albicans and Pseudomonas aeruginosa, both as mono-species biofilms and when grown in a triadic model system. CAP also significantly reduced viability in the nosocomial pathogen, Candida auris. Staphylococcus aureus Newman exhibited a level of tolerance to CAP therapy, both when grown alone or in the triadic model when grown alongside C. albicans and P. aeruginosa. However, this degree of tolerance exhibited by S. aureus was strain dependent. At a microscopic level, biofilm treatment led to subtle changes in morphology in the susceptible biofilms, with evidence of cellular deflation and shrinkage. Taken together, these results indicate a promising application of direct CAP therapy in combatting wound and skin-related biofilm infections, although biofilm composition may affect the treatment efficacy.",
keywords = "Biofilm, Candida auris, Candida albicans, Pseudomonas aeruginosa, Staphylococcus aureus, Heterogeneity, Cold atmospheric plasma, Tolerance",
author = "Abdullah Baz and Ahmed Bakri and Mark Butcher and Bryn Short and Bhagirath Ghimire and Nishtha Gaur and Toby Jenkins and Short, {Robert D.} and Marcello Riggio and Craig Williams and Gordon Ramage and Brown, {Jason L.}",
year = "2023",
month = dec,
day = "31",
doi = "10.1016/j.bioflm.2023.100123",
language = "English",
volume = "5",
journal = "Biofilm",
issn = "2590-2075",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Staphylococcus aureus strains exhibit heterogenous tolerance to direct cold atmospheric plasma therapy

AU - Baz, Abdullah

AU - Bakri, Ahmed

AU - Butcher, Mark

AU - Short, Bryn

AU - Ghimire, Bhagirath

AU - Gaur, Nishtha

AU - Jenkins, Toby

AU - Short, Robert D.

AU - Riggio, Marcello

AU - Williams, Craig

AU - Ramage, Gordon

AU - Brown, Jason L.

PY - 2023/12/31

Y1 - 2023/12/31

N2 - The global clinical and socioeconomic impact of chronic wounds is substantial. The main difficulty that clinicians face during the treatment of chronic wounds is the risk of infection at the wound site. Infected wounds arise from an accumulation of microbial aggregates in the wound bed, leading to the formation of polymicrobial biofilms that can be largely resistant to antibiotic therapy. Therefore, it is essential for studies to identify novel therapeutics to alleviate biofilm infections. One innovative technique is the use of cold atmospheric plasma (CAP) which has been shown to possess promising antimicrobial and immunomodulatory properties. Here, different clinically relevant biofilm models will be treated with cold atmospheric plasma to assess its efficacy and killing effects. Biofilm viability was assessed using live dead qPCR, and morphological changes associated with CAP evaluated using scanning electron microscopy (SEM). Results indicated that CAP was effective against Candida albicans and Pseudomonas aeruginosa, both as mono-species biofilms and when grown in a triadic model system. CAP also significantly reduced viability in the nosocomial pathogen, Candida auris. Staphylococcus aureus Newman exhibited a level of tolerance to CAP therapy, both when grown alone or in the triadic model when grown alongside C. albicans and P. aeruginosa. However, this degree of tolerance exhibited by S. aureus was strain dependent. At a microscopic level, biofilm treatment led to subtle changes in morphology in the susceptible biofilms, with evidence of cellular deflation and shrinkage. Taken together, these results indicate a promising application of direct CAP therapy in combatting wound and skin-related biofilm infections, although biofilm composition may affect the treatment efficacy.

AB - The global clinical and socioeconomic impact of chronic wounds is substantial. The main difficulty that clinicians face during the treatment of chronic wounds is the risk of infection at the wound site. Infected wounds arise from an accumulation of microbial aggregates in the wound bed, leading to the formation of polymicrobial biofilms that can be largely resistant to antibiotic therapy. Therefore, it is essential for studies to identify novel therapeutics to alleviate biofilm infections. One innovative technique is the use of cold atmospheric plasma (CAP) which has been shown to possess promising antimicrobial and immunomodulatory properties. Here, different clinically relevant biofilm models will be treated with cold atmospheric plasma to assess its efficacy and killing effects. Biofilm viability was assessed using live dead qPCR, and morphological changes associated with CAP evaluated using scanning electron microscopy (SEM). Results indicated that CAP was effective against Candida albicans and Pseudomonas aeruginosa, both as mono-species biofilms and when grown in a triadic model system. CAP also significantly reduced viability in the nosocomial pathogen, Candida auris. Staphylococcus aureus Newman exhibited a level of tolerance to CAP therapy, both when grown alone or in the triadic model when grown alongside C. albicans and P. aeruginosa. However, this degree of tolerance exhibited by S. aureus was strain dependent. At a microscopic level, biofilm treatment led to subtle changes in morphology in the susceptible biofilms, with evidence of cellular deflation and shrinkage. Taken together, these results indicate a promising application of direct CAP therapy in combatting wound and skin-related biofilm infections, although biofilm composition may affect the treatment efficacy.

KW - Biofilm

KW - Candida auris

KW - Candida albicans

KW - Pseudomonas aeruginosa

KW - Staphylococcus aureus

KW - Heterogeneity

KW - Cold atmospheric plasma

KW - Tolerance

U2 - 10.1016/j.bioflm.2023.100123

DO - 10.1016/j.bioflm.2023.100123

M3 - Journal article

VL - 5

JO - Biofilm

JF - Biofilm

SN - 2590-2075

M1 - 100123

ER -